Uniti Group Inc. Reports Third Quarter 2023 Results
Reiterates 2023 Outlook for Consolidated Revenue, Adjusted EBITDA and AFFONet loss of $80.9 Million or $0.34 Per Diluted Common Share...
Read moreReiterates 2023 Outlook for Consolidated Revenue, Adjusted EBITDA and AFFONet loss of $80.9 Million or $0.34 Per Diluted Common Share...
Read moreHIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
Read moreNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NEW YORK, Nov. 02, 2023 (GLOBE...
Read moreUpwork Research Institute publishes year-long research revealing three critical attributes of businesses that lead to higher performance, confidence, and revenue...
Read moreNEW YORK, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV Inc., (NASDAQ: AUVI), a pioneer in...
Read morePhase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early...
Read moreSequential Quarterly Revenue Growth of 75% Driven by Enhanced Operational Efficiencies of iSpecimen Marketplace and Rollout of New Business InitiativesLEXINGTON, Mass.,...
Read more- Targeting ADC and Cell & Gene Therapy Customers -WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN),...
Read more– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024...
Read moreNEW YORK, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Image Protect Inc. (OTC:IMTL) (Imageprotectcorporation.com) (“Image Protect” or the...
Read more